BioCentury
ARTICLE | Product Development

INTREPID’s new strategy to help build a pandemic war chest

The INTREPID Alliance has abandoned its fundraising plans, but not its mission to expedite antiviral development for future pandemics

August 2, 2023 11:38 PM UTC

The INTREPID Alliance has abandoned its lofty $1 billion fundraising goal and instead plans to fulfill its mission to accelerate the pipeline of antivirals against future pandemics by coordinating and supporting the development work of others, strengthening the pandemic ecosystem, and collaborating with the 100 Days Mission. 

The alliance, dubbed International Readiness for Preventing Infectious Viral Disease (INTREPID), launched in 2021 to provide an umbrella for the development of antivirals against future pandemic threats and create an avenue for companies and investors to channel their good intentions into development programs. ...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article

BCIQ Company Profiles

Gilead Sciences Inc.